To endorse Cancer Care Ontario's guideline on Active Surveillance for the Management of Localized Prostate Cancer. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines developed by other professional organizations.
Methods
The Active Surveillance for the Management of Localized Prostate Cancer guideline was reviewed for developmental rigor by methodologists. The ASCO Endorsement Panel then reviewed the content and the recommendations.
Results
The ASCO Endorsement Panel determined that the recommendations from the Active Surveillance for the Management of Localized Prostate Cancer guideline, published in May 2015, are clear, thorough, and based upon the most relevant scientific evidence. ASCO endorsed the Active Surveillance for the Management of Localized Prostate Cancer guideline with added qualifying statements. The Cancer Care Ontario recommendation regarding 5-alpha reductase inhibitors was not endorsed by the ASCO panel.
Recommendations
For most patients with low-risk (Gleason score # 6) localized prostate cancer, active surveillance is the recommended disease management strategy. Factors including younger age, prostate cancer volume, patient preference, and ethnicity should be taken into account when making management decisions. Select patients with low-volume, intermediate-risk (Gleason 3 1 4 5 7) prostate cancer may be offered active surveillance. Active surveillance protocols should include prostate-specific antigen testing, digital rectal examinations, and serial prostate biopsies. Ancillary radiologic and genomic tests are investigational but may have a role in patients with discordant clinical and/or pathologic findings. Patients who are reclassified to a higher-risk category (Gleason score $ 7) or who have significant increases in tumor volume on subsequent biopsies should be offered active therapy.
INTRODUCTION
Prostate cancer has the highest incidence rate of any cancer (233,000 men representing 27% of all new cases) and the fourth highest mortality rate (29,480 men representing 10% of all deaths resulting from cancer) in the United States, even when considering both sexes. 1 For this reason, there is great interest in defining optimum strategies for detection, treatment, and follow-up for this patient population. Even in the absence of a formal screening program, 2 prostate cancer is detected early in many cases, is indolent or nonprogressing, and is unlikely to cause morbidity or mortality. 3 To avoid the harms associated with unnecessary treatment, active surveillance (AS) is an option for patients with prostate cancer that is less likely to cause mortality. In 2015, Cancer Care Ontario (CCO) published a Clinical Practice Guideline on Active Surveillance for the Management of Localized Prostate Cancer, 4 and the goal of this assessment was to determine whether to endorse that CCO guideline. This American Society of Clinical Oncology (ASCO) endorsement reinforces the recommendations offered in the CCO guideline on Active Surveillance for the Management of Localized Prostate Cancer 4 and acknowledges the effort put forth by CCO to produce an evidence-based guideline that informs practitioners who care for men with early-stage clinically localized prostate cancer (stages T1 and T2 and Gleason score # 7).
The following are the five research questions on the role of AS in men with localized prostate cancer that were addressed in the original guideline as well as in this endorsement: The original CCO Recommendations are provided in Table 1 and online at http://www.cancercare.on.ca/common/pages/UserFile. aspx?fileId5325696.
OVERVIEW OF THE ASCO GUIDELINE ENDORSEMENT PROCESS
ASCO has policies and procedures for endorsing practice guidelines that have been developed by other professional organizations. The goal of guideline endorsement is to increase the number of high-quality, ASCOvetted guidelines available to the ASCO membership. The ASCO endorsement process involves an assessment by ASCO staff of candidate guidelines for methodologic quality using the Rigour of Development subscale of the Appraisal of Guidelines for Research and Evaluation II instrument (see Methodology Supplement for more detail).
Disclaimer
The clinical practice guidelines and other guidance published herein are provided by the American Society of Clinical Oncology, Inc. ("ASCO") to assist providers in clinical decision making. The information therein should not be relied on as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Furthermore, the information is not intended to substitute for the independent professional judgment of the treating provider because the information does not account for individual variation among patients. Recommendations reflect high, moderate, or low confidence that the recommendation reflects the net effect of a given course of action. The use of words like "must," "must not," "should," and "should not" indicate that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of this information is voluntary. ASCO provides this information on an "as is" basis and makes no warranty, expressed or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising from or related to any use of this information or for any errors or omissions.
Guideline and Conflicts of Interest
The Endorsement Panel (Appendix Table A1 , online only) was assembled in accordance with ASCO's Conflict of Interest Policy Implementation for Clinical Practice Guidelines ("Policy" found at www.asco.org/rwc). All members of the Endorsement Panel completed ASCO's disclosure form, which requires disclosure of financial and other interests, including relationships with commercial entities that are reasonably likely to experience direct regulatory or commercial impact as the result of promulgation of the guideline. Categories for disclosure include employment; leadership; stock or other ownership; honoraria; consulting or advisory role; speakers' bureau; research funding; patents, royalties, other intellectual property; expert testimony; travel, accommodations, expenses; and other relationship. In accordance with the Policy, the majority of the members of the Endorsement Panel did not disclose any relationships constituting a conflict under the Policy. Not endorsed.
Not endorsed.
(continued on following page) 7) .
Summary of the Active Surveillance for the Management of Localized Prostate Cancer Guideline Development Methodology
The CCO guideline 4 was developed by a working group that included experts in urology, pathology, radiation oncology, and research methodology. A systematic review of the literature, covering the years 1996 through 2013 was performed by using the Ovid MEDLINE and EMBASE databases. In addition, conference proceedings for the following were also searched for the years 2010 through 2012: ASCO Annual Meeting, ASCO Genitourinary Cancers Symposium, American Urological Association, European Association of Urology, Canadian Urological Association, and American Society for Radiation Oncology. Details of the search strategies and the study inclusion criteria and outcomes of interest are available at http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId5325696.
The literature search identified 62 studies eligible for inclusion in the guideline. The CCO working group reviewed data from practice guidelines, systematic reviews, randomized controlled trials, and other comparative studies that reported on AS in males with newly diagnosed early-stage localized prostate cancer (stages T1 and T2 and Gleason score # 7) that included 30 or more patients. The panel provided evidence-based recommendations for all clinical questions informed by expert consensus.
RESULTS OF THE ASCO METHODOLOGY REVIEW
The methodology review of the CCO guideline 4 was completed independently by two ASCO guideline staff members using the Rigour of Development subscale from the Appraisal of Guidelines for Research and Evaluation II instrument. Detailed results of the scoring for this guideline are available upon request to guidelines@ asco.org. Overall, the Active Surveillance for the Management of Localized Prostate Cancer guideline scored 6.5 of 7, with a Rigour of Development score of 98%. The preliminary ASCO content reviewers of the Active Surveillance for the Management of Localized Prostate Cancer guideline, as well as the ASCO Endorsement Panel, found the recommendations well supported in the original guideline. Each section, including the guideline recommendations, the evidentiary base, the development methods, and external review process, was clear and well referenced in the systematic review.
This is the most recent information as of the publication date. For updates and the most recent information and to submit new evidence, please visit www.asco.org/endorsements/ActiveSurveillance and the ASCO Guidelines Wiki (www.asco.org/guidelineswiki). 
METHODS AND RESULTS

RESULTS OF ASCO CONTENT REVIEW
The ASCO Endorsement Panel reviewed the Active Surveillance for the Management of Localized Prostate Cancer guideline and concurred that the recommendations are clear, thorough, and based on the most relevant scientific evidence in this content area and present options that will be acceptable to many patients. Overall, the ASCO Endorsement Panel agrees with the recommendations as stated in the guideline, with the minor qualifications discussed here.
DISCUSSION
The ASCO Endorsement Panel wants to highlight and qualify some of the statements from the Active Surveillance for the Management of Localized Prostate Cancer 4 guideline. The distinction between AS and watchful waiting is important for clinical decision making. AS, which carries a curative intent and involves regular monitoring with PSA, DRE, and biopsy (see Recommendation 3), is appropriate for patients who have sufficient life expectancy 6 to benefit from active treatment if disease progression is detected. Note that calculation of life expectancy is based on a variety of individual factors and circumstances. A number of life expectancy calculators (eg, http://www.socialsecurity. gov/OACT/population/longevity.html) are available in the public domain; however, ASCO does not endorse any one calculator over another. For patients with a life expectancy of less than 5 years, watchful waiting (cessation of routine monitoring with treatment initiated only if symptoms develop) is appropriate and further reduces the issue of overtreatment in prostate cancer, including ASCO qualifying statement: It is known that there is heterogeneity within this population and therefore factors such as younger age, high-volume Gleason 6 cancer, patient preference, and/or African American ethnicity should be taken into account in this recommendation. Young patients (younger than age 55 years) with high-volume Gleason 6 cancer should be closely scrutinized (continued on following page) biopsies which carry a small but nonzero risk of infection and hospitalization. 7 AS is the recommended disease management strategy for low-risk prostate cancer. Older patients may start on AS, potentially transition to watchful waiting if there is no disease progression, and be able to avoid treatment altogether. However, the ASCO Endorsement Panel recognizes that there is disease heterogeneity, and select patients with low-risk prostate cancer may appropriately choose immediate treatment instead of AS, including patients who are younger, have high-volume Gleason 6 cancer, 8 and have African American ethnicity, 9 because these patients have a higher likelihood for disease progression during their lifetime. A potential drawback to AS is the use of more intensive treatments when cancer progresses. That is, RT for intermediate-or high-risk prostate cancer often involves concurrent androgen deprivation therapy or external beam RT with or without brachytherapy boost; patients who undergo RP with intermediate-or high-risk cancer may be more likely to need adjuvant RT. However, this needs to be balanced against the benefits of AS, including delaying treatment and associated shortterm and long-term adverse effects, and decisions need to take patient preference into account.
Use of ancillary tests beyond DRE, PSA, and biopsy to improve patient selection or as part of monitoring in an AS regimen remains investigational. Although there is a potential for genomic tests 10-12 that use biopsy tissue to predict patients who are more rather than less likely to have disease progression and cancer-specific mortality and for multiparametric magnetic resonance imaging (mpMRI) 13 to guide biopsies to find more clinically aggressive disease, 14 prospective validation of these tests is needed to assess their impact on patient outcomes such as survival. Selective use of these ancillary tests in patients with discordant clinical and/or pathologic findings may be appropriate.
There is no clear role for 5ARIs in a routine AS regimen. 5ARIs such as finasteride and dutasteride block the conversion of testosterone to dihydrotestosterone. 15 A randomized trial compared dutasteride with placebo in 302 patients undergoing AS for low-
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for the presence of higher-grade cancer, and definitive therapy may be warranted for select patients. For patients with limited life expectancy (< 5 years) and low-risk cancer, watchful waiting may be more appropriate than active surveillance. 3 1 4) being considered for AS should include only those men with lowvolume Gleason pattern 4 pathology and/or age older than 75 years. Because of known interobserver variability associated with the identification of minor Gleason pattern 4 elements, prospective intradepartmental consultation with colleagues should be considered a cornerstone of quality assurance in this area. For patients with limited life expectancy (< 5 years), watchful waiting may be more appropriate than AS.
3. The AS protocol should include the following tests:
• A PSA test every 3 to 6 months • DRE at least every year • At least a 12-core confirmatory transrectal ultrasound guided biopsy (including anterior directed cores) within 6 to 12 months, and then serial biopsy every 2 to 5 years thereafter or more frequently if clinically warranted. Men with limited life expectancy may transition to watchful waiting and avoid further biopsies.
The AS protocol may include ancillary tests that are still under investigation. These could include multiparametric MRI (mpMRI) and/ or genomic testing. mpMRI and genomic testing may be indicated when a patient's clinical findings are discordant with the pathologic findings and could be useful in identifying occult cancers or changes indicative of tumor progression in patients at risk. These tests may also be helpful when the decision regarding AS versus active treatment is uncertain (eg, in cases of low-volume Gleason 3 1 4). mpMRI should not be used as a replacement for rebiopsy.
4.
For patients undergoing AS who are reclassified to a higher-risk category, defined by repeat biopsy showing Gleason score $ 7 and/or significant increases in the volume of Gleason 6 tumor, consideration should be given to active therapy (eg, RP or RT).
Additional Resources
More information, which may include Data and Methodology Supplements, slide sets, and clinical tools and resources, is available at www.asco.org/endorsements/ActiveSurveillance and www.asco.org/guidelineswiki. Patient information is available at www.cancer.net. A link to the Active Surveillance for the Management of Localized Prostate Cancer guideline can be found at http://www.cancercare.on. ca/common/pages/UserFile.aspx?fileId5325696.
ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate.
risk prostate cancer. 16 After 3 years of follow-up, there was no significant difference between the two groups with respect to pathologic disease progression (defined as increase in either disease volume and/or Gleason score; 29% dutasteride versus 33% placebo; P 5 .079). 17 There was also no difference in progression to Gleason 7 or higher disease. It should also be noted that 5ARIs significantly alter PSA kinetics, and clinical decisions regarding rebiopsy in patients taking these medications need to take this into account. Although the CCO guideline included a recommendation stating that daily 5ARIs may have a role in men receiving AS, the ASCO Endorsement Panel chose not to include this recommendation, because the evidence does not support the routine use of 5ARIs in this setting. The ASCO Endorsement Panel was in agreement with the CCO guideline that there is currently insufficient evidence to make recommendations with regard to the personnel who should be responsible for the management of AS protocols. However, in the opinion of the ASCO Endorsement Panel, a multidisciplinary team approach should be taken when a change to active treatment is considered.
ENDORSEMENT RECOMMENDATION
ASCO endorses all but one recommendation from CCO's Active Surveillance for the Management of Localized Prostate Cancer 4 guideline published in the Canadian Urological Association Journal, with qualifying statements.
ADDITIONAL RESOURCES
More information, which may include a Data Supplement, a Methodology Supplement, slide sets, and clinical tools and resources, is available at www.asco.org/endorsements/ActiveSurveillance and www.asco.org/guidelineswiki. Patient information is available at www.cancer.net. Visit www.asco.org/guidelineswiki to provide comments on the guideline or to submit new evidence.
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